<DOC>
	<DOCNO>NCT02408432</DOCNO>
	<brief_summary>The goal clinical research study learn add mesenchymal stem cell ( MSCs ) standard care drug help control heart failure may cause anthracyclines ( type chemotherapy drug use cancer treatment ) . The safety MSCs also study . MSCs type stem cell remove bone marrow grow many different cell type use treat cancer disease , heart failure . The MSCs use study collect healthy donor store grown laboratory MD Anderson .</brief_summary>
	<brief_title>Intravenous Administration Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells ( MSCs ) Patients With Recent Onset Anthracycline-Associated Cardiomyopathy</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , randomly assign ( roll dice ) 1 2 study group . This do one know one study group well , , bad group . - If Group 1 , receive MSCs standard care drug heart failure . - If Group 2 , receive standard care drug heart failure . You 2 3 chance assign Group 1 1 3 chance assign Group 2 . Study Drug Administration : If Group 1 , receive MSCs vein 10-20 minute 1 time week 4 week outpatient clinic . You remain clinic 6 hour MSC infusion study staff may check side effect . Both group also receive standard care drug heart failure . The study doctor tell drug take , risk , take . Study Visits : On Days 1 , 14 , 21 , 28 ( +/- 5 day ) , Group 1 , blood ( 4 tablespoon ) draw routine test check heart liver function . One ( 1 ) time month Months 2-6 , participant : - You physical exam . - Blood ( 4 tablespoon ) draw routine test check heart liver function . At Months 3 6 , blood also use biomarker test . - At Months 1 , 3 , 6 , EKG ECHO . - At Months 3 6 , perform physical test , include walk 6 minute . At Month 12 , physical exam , EKG , ECHO . Length Study : If Group 1 , able receive 4 infusion MSCs . You longer able receive MSCs disease get bad , intolerable side effect occur , unable follow study direction . Your active participation study Month 12 . This investigational study . MSCs FDA-approved commercially available . They use research purpose . The study doctor explain design work . Up 45 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>1 . Patients LVEF &lt; /= 40 % treatment anthracyclines malignancy dose without evidence cause cardiomyopathy . 2 . 1880 year age . 3 . Documented NYHA class I , II III . 4 . Myocardial Volume Oxygen ( MVO2 ) &lt; 15ml/Kg/min . 5 . Been treated appropriate maximal medical therapy heart failure . 6 . Able perform Exercise MVO2 6 minute walk test . 7 . Patient legally authorize representative able sign inform consent . 8 . Patients persistent LV dysfunction 90 day discontinuation trastuzumab . 1 . Evidence Ischemic Heart Disease determine study Cardiologist . 2 . Significant Valvular Disease . ( AS AVA &lt; 1.5 severe AR MR ) . 3 . History Familial Cardiomyopathy . 4 . Recent document myocarditis within 2 month consent . 5 . History Infiltrative cardiomyopathy restrictive cardiomyopathy . 6. eGFR &lt; 50 Mayo Cockcroft formula . 7 . Creatinine clearance &lt; 50 ml/min . 8 . Liver function test &gt; 3 x upper limit normal . 9 . NYHA class IV heart failure . 10 . Inotropic dependence . 11 . Unstable lifethreatening arrhythmia . 12 . Coagulopathy INR &gt; 1.5 . 13 . Mechanical Bioprosthetic heart valve . 14 . Cardiogenic shock . 15 . Breastfeeding and/or pregnant woman . 16 . Autoimmune disorder current immunosuppressive therapy . 17 . Active infection respond appropriate therapy determine Study Chair . 18 . Trastuzumab treatment within last 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Blood And Marrow Transplantation</keyword>
	<keyword>Left ventricular dysfunction</keyword>
	<keyword>LV</keyword>
	<keyword>Heart failure secondary chemotherapy anthracyclines</keyword>
	<keyword>Allogeneic human mesenchymal stem cell</keyword>
	<keyword>hMSCs</keyword>
	<keyword>Standard care drug heart failure</keyword>
</DOC>